Introduction
============

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin\'s lymphoma (NHL), accounting for 31% of all cases of NHL in western countries and \>40% of NHL cases in Asia ([@b1-br-0-0-1222]). With the currently available options for chemoimmunotherapy and systemic disease control, the 5-year survival rate of patients with DLBCL has improved (60-90%) ([@b4-br-0-0-1222],[@b5-br-0-0-1222]). Secondary involvement of the central nervous system (CNS) in patients with DLBCL is a relatively uncommon manifestation, encountered in only 5-7% of cases ([@b6-br-0-0-1222]); however, its incidence is higher in patients with certain high-risk clinical characteristics at the time of diagnosis ([@b10-br-0-0-1222]). These risk factors include a high International Prognostic Index score ([@b11-br-0-0-1222]); involvement of more than two extranodal sites, retroperitoneal lymph node involvement, elevated lactate dehydrogenase level, or DLBCL originating from high-risk locations, such as the bone marrow, paranasal sinuses, testis, breast, adrenal gland and kidney ([@b18-br-0-0-1222],[@b12-br-0-0-1222]). The outcome following CNS relapse is poor, with the overall survival shortened to \<6 months ([@b17-br-0-0-1222]). Intrathecal (IT) and intravenous high-dose (HD) methotrexate are common methods of CNS prophylaxis ([@b11-br-0-0-1222]). Given the low CNS relapse rate in DLBCL, and evaluating the benefits against the adverse effects, the application of CNS prophylaxis for DLBCL is not widely implemented ([@b12-br-0-0-1222],[@b18-br-0-0-1222]). As it is preferable that CNS prophylaxis is administered during primary chemotherapy, the identification of patients with DLBCL who are at high risk for subsequent CNS recurrence at the time of diagnosis is crucial. There is currently no consensus regarding a diagnostic algorithm for CNS involvement in DLBCL. Neurological symptoms, CNS imaging, stereotactic biopsy and cerebrospinal fluid (CSF) cytology are the current methods commonly used for diagnosis and evaluating patients at high risk of, or with suspected, CNS involvement ([@b19-br-0-0-1222]). CSF examination includes cytology, flow cytometric analysis and biochemical biomarkers. CSF cytology is a specific diagnostic approach, but it can only detect malignant lymphoid cells in 40% of patients with suspected CNS dissemination ([@b20-br-0-0-1222]). Flow cytometric analysis of the CSF has already demonstrated increased sensitivity ([@b21-br-0-0-1222]); however, since the introduction of rituximab, the majority of CNS relapse events are parenchymal (65-70%), and CSF flow cytometry is of limited diagnostic value in such cases ([@b22-br-0-0-1222]). Biochemical biomarker examination of the CSF exhibits higher sensitivity compared with CSF cytology (58-85%), but only a moderate improvement in specificity (85%) ([@b25-br-0-0-1222]). Therefore, it is necessary to develop a convenient and accurate method for evaluating the risk of CNS involvement at diagnosis in order to implement adequate CNS prophylaxis.

Quantitative global proteomics is an advanced approach to the accurate characterization of proteins in complex biological systems, which is applied to identify unbiased biomarkers or key proteins associated with specific physiological and pathological states ([@b26-br-0-0-1222]). The advantages of label-free quantification liquid chromatography-mass spectrometry (LC/MS) analysis are as follows: First, the cost, procedure and artificial expenses of labeling samples are eliminated. Second, it has the capacity to quantify a large number of proteins per LC/MS measurement ([@b27-br-0-0-1222]). By using proteomics, numerous studies have identified potential CSF biomarkers of neurological diseases, including amyotrophic lateral sclerosis, cerebral malaria and tuberculous meningitis ([@b28-br-0-0-1222]). Quantitative proteomics of CSF samples from serial lumbar punctures during induction in patients with acute lymphoblastic leukemia have found potential predictive markers of CNS thrombosis ([@b31-br-0-0-1222]). However, to the best of our knowledge, global proteomic profiling of CSF from patients with DLBCL has not been reported to date. Therefore, in the present study, a high-throughput label-free quantitative proteomic analysis was performed to identify proteins present in the CSF of patients with DLBCL with CNS recurrence compared with those in healthy controls, in order to identify potential CSF biomarkers for patients at high risk of developing CNS recurrence.

Materials and methods
=====================

### Subjects

The subjects included four patients diagnosed with DLBCL at the West China Medical Center of Sichuan University (Chengdu, China), and six healthy control subjects recruited at the Physical Examination Center of West China Hospital, Sichuan University from January 2016 to January 2017. The patients with DLBCL were evaluated for CNS recurrence based on the clinical characteristics at the time of diagnosis. The healthy control subjects were defined as individuals without active DLBCL or any neurological complaints. Informed consent was obtained from all the participants and the study protocol was approved by the Medical Ethics Committee of West China Hospital, Sichuan University.

### Sample preparation

The CSF was collected in plastic tubes containing Trasylol (Bayer Diagnostics) to prevent proteolysis. Following clinical analysis, the CSF samples were centrifuged at 3,000 x g at 4˚C for 5 min. All supernatant, aside from the last 0.5 ml, was transferred to a new container and then immediately frozen at -20˚C and stored at -80˚C until further use. A total of 30 µl CSF were solubilized in cold RIPA buffer \[150 mm NaCl, 50 mm Tris-HCl (pH 7.61), NP-40, 1% deoxycholic acid\] with phosphatase and protease inhibitors on ice for 10 min. The samples were then centrifuged at 20,000 x g at 4˚C for 5 min and quantified using a Bradford protein assay. Buffer containing 100 mM NH~4~HCO~3~ was added to equivalent proteins at 100 µg for trypsin digestion. The protein samples were then treated with 5 mM DL-dithioreitol (DTT, Sigma-Aldrich; Merck KGaA) and incubated for 60 min at 37˚C. To alkylate the cysteines, iodoacetamide (IAM; Sigma-Aldrich; Merck KGaA) was added to a final concentration of 15 mM, followed by incubation in the dark at room temperature for 45 min. A total of 30 mM L-cysteine (Promega Corporation) was required for blocking redundant IAM. The protein samples were digested with trypsin (Promega Corporation) overnight at 37˚C at a protein: Trypsin ratio of 50:1. The digestion reaction was terminated by heating the samples to 90˚C to inactivate the enzyme. Finally, C18 ZipTip (Merck KGaA) was used for desalination of the in-solution digested samples.

### MS analysis

Prior to being analyzed by LC-MS/MS, coupling an Easy nLC1000 nanoflow HPLC system to the Q-Exactive quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific, Inc.), all samples were lyophilized and resuspended in buffer A \[2% acetonitrile (ACN) + 0.1% formic acid (FA)\]. A two-column setup was used. Both the trap column (100 µm x 2 cm) and analytical column (75 µm x 12 cm) were packed in-house with Magic C18 AQ resin (200A, 5 µm; Michrom Bioresources). The composition (v/v) of the LC buffer was as follows; buffer A: 97.9% water, 2% ACN and 0.1% FA; and buffer B: 95% ACN, 4.9% water and 0.1% FA. The mobile phases were initially 4% B for 3 min, reaching 22% B between 3 and 43 min at a flow rate of 400 nl/min. An increase to 30% B over the next 8 min was at 300 nl/min. An increase to 95% B occurred between 52 and 60 min and lasted for the final 5 min. The mass spectrometer was set to perform data-dependent acquisition in positive ion mode. Full MS spectra were acquired at a resolution of 70,000 over a mass range of 350-1,800 m/z. The automatic gain control (AGC) value was set to 3x10^6^ with maximum fill times of 20 ms. For the MS/MS scans, the 20 most intense parent ions were selected with a 1.6 m/z mass window and fragmented with a normalized collision energy of 27%. The MS/MS spectra were recorded at a resolution of 17,500, with the AGC value target set to 1x10^6^ and a maximum fill time of 64 ms. Parent ions with a single charge or with unassigned charge states were not selected for fragmentation, and the intensity threshold for selection was set to 3.1x10^6^. Dynamic exclusion with a time window of 30 sec was applied.

### Data analysis

The raw files acquired on the Q-Exactive plus were subjected to data analysis using MaxQuant software (version 1.3, <https://maxquant.org/>). The searches were performed against the SwissProt human database (updated on 05/2012, 86,758 sequences, <https://www.uniprot.org/statistics/Swiss-Prot>). The following settings were selected for analysis: Cysteine carbamidomethylation was set as a fixed modification. Oxidation of methionine and acetylation of the protein N-terminal were set as variable modifications. Precursor peptide mass deviation was set to 10 ppm and fragment ion mass deviation was set to 0.02 Da. The maximum number of missed trypsin cleavages was set to two in the searches. The peptide false discovery rate was calculated with searches against the corresponding reverse database and set to 0.01. Label-free quantification was performed in MaxQuant, as described previously ([@b32-br-0-0-1222]). Peptides with the same mass but different oxidation states were considered to be the same peptide in all data analyses, in case the oxidation was due to sample manipulation.

### Proteomics analysis

The heat map of Global protein expression profiles was carried out by R version. The enrichment functional analysis for Gene Ontology (GO) terms and KEGG pathways of the identified proteins was performed using David 6.7 (<https://david-d.ncifcrf.gov/>). The protein-protein interacts network (PPIN) of the proteins selected in this study was constructed by the String database (<https://string-db.org/>). Then the hub gene network modules from the PPIN were done by MCODE (Cytoscape 3.6.0, <https://cytoscape.org/>).

### Statistical analysis

Statistical analyses were performed with GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA) and the data were expressed as mean ± standard deviations (SD). P\<0.05 was considered statistically significant. Multiple comparisons of different groups were performed using paired t-test.

Results
=======

### Subject characteristics

CSF samples were obtained from the four patients with DLBCL with CNS involvement and six healthy controls. The DLBCL group included two men and two women. The mean age of the patients was 45 years (range, 20.25-62.50 years). The healthy control group included three men and three women, with a mean age of 40.5 years (range, 26.50-55.25 years). There were no statistically significant differences between the two groups in terms of age or sex (P\>0.05). The demographic details of the patients with DLBCL are summarized in [Table SI](#SD1-br-0-0-1222){ref-type="supplementary-material"}.

### Quantitative proteomics of CSF

A total of 80 proteins from the four patients and six healthy control subjects were identified using label-free LC-MS/MS, and only 53 differentially expressed proteins with \>1 log~2~ fold change and P\<0.05 between the two groups were selected for further analysis ([Fig. 1A](#f1-br-0-0-1222){ref-type="fig"}; [Table I](#tI-br-0-0-1222){ref-type="table"}). Heat maps of all proteins selected are shown in [Fig. 1B](#f1-br-0-0-1222){ref-type="fig"}. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was utilized for the functional annotation of the 53 differential proteins. According to the Gene Ontology database, certain proteins can be attributed to multiple cellular components, functions and/or processes. As shown in [Fig. 2A](#f2-br-0-0-1222){ref-type="fig"}, the 'biological processes' analysis revealed significant enrichment in platelet degranulation, innate immune response and cell adhesion. The analysis of 'molecular function' indicated that the differential CSF proteins were mainly associated with protein binding, calcium ion binding and serine-type endopeptidase activity ([Fig. 2B](#f2-br-0-0-1222){ref-type="fig"}). The 'cellular component' analysis ([Fig. 2C](#f2-br-0-0-1222){ref-type="fig"}) revealed that extracellular exosome, extracellular space and blood microparticle were the most over-represented terms (P\<0.001). Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed three canonical pathways: Complement and coagulation cascades, prion diseases and *Staphylococcus aureus* infection, which provided insight into the function of the 53 differential proteins in the CSF ([Fig. 2D](#f2-br-0-0-1222){ref-type="fig"}).

### Protein-protein interaction (PPI) network (PPIN) construction

Based on the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database, a PPIN of 53 proteins was constructed ([Fig. 3](#f3-br-0-0-1222){ref-type="fig"}). As shown in [Fig. 4](#f4-br-0-0-1222){ref-type="fig"}, two hub gene network modules were obtained from the PPIN analyzed by MCODE. There were 10 genes with 45 interactions in module 1 (MCODE score 8.182), and six genes with 14 interactions in module 2 (MCODE score 4). In order to further understand the function of the obtained hub modules, they were analyzed using the DAVID database ([Table II](#tII-br-0-0-1222){ref-type="table"}). The first module was mainly enriched in platelet degranulation, and the complement and coagulation cascades. The second module was mainly related to neuropeptide signaling pathway and secretion. Furthermore, secreted protein acidic and rich in cysteine (SPARC) was found to be at the center of network module 1 with the highest fold change (log~2~FC: 4.13). In network module 2, proenkephalin (PENK) was the protein with the highest fold change (log~2~FC: 4.13). These findings indicated that the decreased expression of SPARC and PENK in the CSF was the most sensitive, and these proteins may serve as early-phase biomarkers to evaluate the risk of CNS involvement in DLBCL.

Discussion
==========

In the present study, high-throughput quantitative proteomic analysis was applied to analyze the expression of proteins in the CSF of patients with DLBCL. Four CSF samples from patients with DLBCL with CNS involvement were compared with six CSF samples from healthy control subjects. Among the 53 differentially expressed proteins identified, the most significantly altered proteins, namely SPARC and PENK, appear to hold promise as a diagnostic biomarker to evaluate the risk of CNS involvement in DLBCL, as they exhibited the highest fold change and cross-talk with other proteins found to be altered in the CSF of patients with DLBCL.

SPARC is a 43-kDa glycoprotein, also referred to as BM-40 or osteonectin ([@b33-br-0-0-1222]). SPARC is a multifunctional protein that can modulate extracellular matrix assembly, integrin activity and growth factor signaling ([@b34-br-0-0-1222]). In cancer, SPARC has different functions, depending on the tissue and cell type. In certain types of cancer, such as melanoma and glioma, SPARC is associated with a highly aggressive tumor phenotype ([@b38-br-0-0-1222]). However, in neuroblastomas, and ovarian, colorectal and primitive neuroectodermal tumors, SPARC-induced changes in the tumor microenvironment can suppress tumor progression ([@b38-br-0-0-1222],[@b39-br-0-0-1222]). It was previously reported that patients with DLBCL with any SPARC-positive cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC-positivity in the microenvironment also had a significantly longer event-free survival ([@b40-br-0-0-1222]). These findings suggested that SPARC-positive stromal cells in the microenvironment of DLBCL may act as tumor suppressors. In the present study, the expression of SPARC was also found to be significantly downregulated in the CSF of patients with DLBCL with CNS involvement, which was in accordance with the suppressive function of SPARC in DLBCL. The mechanism underlying the suppressive effect of SPARC on the progression of DLBCL and improved patient survival rates remains unclear. Possible explanations include the decreased production of necessary growth factors, alterations of the extracellular matrix preventing tumor cell interactions, and decreased integrin production by tumor cells, resulting in altered extracellular matrix interactions ([@b40-br-0-0-1222]).

PENK is a nuclear protein responsive to growth arrest and differentiation signals, and is required for the induction of apoptosis ([@b41-br-0-0-1222]). It is reported that the expression of PENK is downregulated by two proto-oncogenes, Fos and Jun ([@b42-br-0-0-1222]). Previous studies have reported that PENK is downregulated in prostate cancer and glioblastoma; PENK was also reported to be aberrantly methylated in colorectal, bladder and pancreatic cancer ([@b43-br-0-0-1222]). PENK has been shown to stimulate stress-activated apoptosis, particularly under treatment with chemotherapeutic drugs, in colon cancer. In the present study, PENK was found to be downregulated in the CSF of patients with DLBCL with CNS involvement. These findings suggest that the tumors may attenuate apoptosis by downregulating the protein expression of PENK.

Taken together, these data indicate that the decreased expression of certain proteins in the CSF of patients with DLBCL with CNS involvement is closely associated with the antitumor and/or anti-invasion process. Therefore, detecting the concentration of proteins, including SPARC and PENK, offers a potential method for identifying patients with DLBCL at risk of subsequent CNS involvement. In the present study, the small sample size is a limitation, but it also provides future direction to collect additional samples for further investigation.

In conclusion, through high-throughput label-free quantitative proteomic analysis of the CSF from patients with DLBCL and healthy control subjects, 53 differentially expressed proteins and two gene (protein) hub network modules were identified in total. Protein biomarkers, including SPARC and PENK, which were found to be closely associated with DLBCL invasion, were expressed at low levels in the CSF of patients with early-stage DLBCL. Therefore, they may be valuable biomarkers for assessing the risk of CNS involvement in DLBCL at initial diagnosis. Considering the potential limitations of the present study in terms of design, technique and analytical strategy, additional investigations with larger cohorts of patients are required to confirm the robustness of these findings.
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###### 

Differential proteins identified by label-free LC-MS/MS ordered by log2FC.

  Protein ID   Gene name   Protein name                                                       Log2FC
  ------------ ----------- ------------------------------------------------------------------ --------
  Q13822       ENPP2       Ectonucleotide pyrophosphatase/phosphodiesterase family member 2   5.32
  Q16270       IGFBP7      Insulin-like growth factor-binding protein 7                       4.97
  P08294       SOD3        Extracellular superoxide dismutase                                 4.29
  O94985       CLSTN1      Calsyntenin-1                                                      4.18
  P09486       SPARC       Secreted protein acidic and rich in cysteine                       4.13
  P10643       C7          Complement component C7                                            4.11
  P01210       PENK        Proenkephalin                                                      3.95
  P00736       C1R         Complement C1r                                                     3.94
  Q08380       LGALS3BP    Galectin-3-binding protein                                         3.92
  Q8WXD2       SCG3        Secretogranin-3                                                    3.82
  P02747       C1QC        Complement C1q subcomponent subunit C                              3.69
  P14618       PKM         Pyruvate kinase                                                    3.41
  P16870       CPE         Carboxypeptidase E                                                 3.33
  P00751       CFB         Complement factor B                                                3.29
  P05155       SERPING1    Plasma protease C1 inhibitor                                       3.19
  P09871       C1S         Complement C1s subcomponent                                        3.14
  P18065       IGFBP2      Insulin-like growth factor-binding protein 2                       3.12
  P01034       CST3        Cystatin-C                                                         3.11
  P00450       CP          Ceruloplasmin                                                      3.10
  P02751       FN1         Fibronectin                                                        3.10
  P05060       CHGB        Secretogranin-1; CCB peptide                                       3.08
  Q92823       NRCAM       Neuronal cell adhesion molecule                                    3.08
  Q15113       PCOLCE      Procollagen C endopeptidase enhancer 1                             3.03
  Q12860       CNTN1       Contactin-1                                                        2.95
  P02766       TTR         Transthyretin                                                      2.93
  Q99435       NELL2       Neural epidermal growth factor-like like 2                         2.92
  P19652       ORM2        Alpha-1-acid glycoprotein 2                                        2.85
  P02763       ORM1        Alpha-1-acid glycoprotein 1                                        2.84
  P10909       CLU         Clusterin                                                          2.77
  O95502       NPTXR       Neuronal pentraxin receptor                                        2.64
  P51693       APLP1       Amyloid-like protein 1; C30                                        2.60
  Q12805       EFEMP1      EGF-containing fibulin-like extracellular matrix protein 1         2.58
  P10645       CHGA        Chromogranin-A                                                     2.46
  P20774       OGN         Mimecan                                                            2.44
  P05067       APP         Amyloid beta A4 protein                                            2.33
  O15240       VGF         Neurosecretory protein VGF                                         2.32
  P55058       PLTP        Phospholipid transfer protein                                      2.32
  Q14624       ITIH4       Inter-alpha-trypsin inhibitor heavy chain H4                       2.31
  Q92876       KLK6        Kallikrein-6                                                       2.30
  P01857       IGHG1       Ig gamma-1 chain C region                                          2.29
  P24592       IGFBP6      Insulin-like growth factor-binding protein 6                       2.27
  O00533       CHL1        Neural cell adhesion molecule L1-like protein                      2.24
  P01019       AGT         Angiotensinogen                                                    2.19
  P01860       IGHG3       Ig gamma-3 chain C region                                          2.10
  Q9NQ79       CRTAC1      Cartilage acidic protein 1                                         1.87
  P02753       RBP4        Retinol-binding protein 4                                          1.84
  P01009       SERPINA1    Alpha-1-antitrypsin                                                1.79
  O43505       B4GAT1      Beta-1,4-glucuronyltransferase 1                                   1.68
  P25311       AZGP1       Zinc-alpha-2-glycoprotein                                          1.52
  Q14515       SPARCL1     SPARC-like protein 1                                               1.50
  P13591       NCAM1       Neural cell adhesion molecule 1                                    1.34
  Q9UBP4       DKK3        Dickkopf-related protein 3                                         1.27
  P01834       IGKC        Ig kappa chain C region                                            1.14

log2FC, log2 fold change.

###### 

Functional enrichment analysis of the hub modules.

  Module   Database     GO and pathway                                  Genes (n)   P-value
  -------- ------------ ----------------------------------------------- ----------- -----------------------------------------------------
  1        GO term-BP   Platelet degranulation                          9           0.15
                        Acute-phase response                            5           \<0.01^[b](#tfn2-br-0-0-1222){ref-type="table-fn"}^
                        Negative regulation of endopeptidase activity   4           \<0.01^[b](#tfn2-br-0-0-1222){ref-type="table-fn"}^
                        Cell adhesion                                   3           0.02^[a](#tfn1-br-0-0-1222){ref-type="table-fn"}^
           KEGG         Complement and coagulation cascades             2           0.03^[a](#tfn1-br-0-0-1222){ref-type="table-fn"}^
  2        GO term-BP   Neuropeptide signaling pathway                  2           0.02^[a](#tfn1-br-0-0-1222){ref-type="table-fn"}^
                        Secretion                                       3           0.02^[a](#tfn1-br-0-0-1222){ref-type="table-fn"}^
                        G-protein coupled receptor signaling pathway    3           0.03^[a](#tfn1-br-0-0-1222){ref-type="table-fn"}^

^a^P\<0.05;

^b^P\<0.01. GO, Gene Ontology; BP, biological process; KEGG, Kyoto Encyclopedia of Genes and Genomes.

[^1]: \*Contributed equally
